For Healthcare Professionals

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies


About the study

This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Main Inclusion Criteria:

  1. Diagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
  2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  3. Agreement to use contraception during the study and for 90 days after the last dose of study drugs if sexually active and able to bear or beget children.


Exclusion Criteria

  1. A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
  2. Central nervous system (CNS) involvement by lymphoma/leukemia
  3. Any therapeutic antibody within 4 weeks of first dose of study drugs.
  4. The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drugs is < 5 times the half-life of the previously administered agent(s).
  5. ANC < 0.5 x 10^9/L or platelet count < 50 x 10^9/L unless due to disease involvement in the bone marrow.
  6. Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Non-Hodgkins Lymphoma,Multiple Myeloma,B-All

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Dec 31, 2025

Treatment type



Acerta Pharma BV identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.